ClinicalTrials.gg
Active, not recruitingNCT06631989Updated Nov 12, 2026

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

A Phase 1/2 interventional study of WSD0922-FU in EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer, sponsored by Wayshine Biopharm, Inc.. Active, not recruiting at 12 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Wayshine Biopharm, Inc. · Phase 1/2, Interventional, and Treatment

Updated Nov 12, 2026Now Active, not recruitingEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 762 open to participants now, 987 under way, 202 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Enrollment
1,011th of 1,595
60 · median 100
Started
2024
with 202 others
Phase 1/2
160 of 1,882
83 open now
Primary completion
2027-06
later than 552 of 986 live
Registered
1,380th of 1,882
by date

Among the 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 1,011th largest by enrollment of the 1,595 interventional ones that give a count, is one of 203 that started in 2024, is one of 160 in phase 1/2, reaches primary completion later than 552 of the 986 other live ones, and was the 1,380th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

762 of the 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

757 more — sign in →

All 762 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, open label, single-arm phase I/II clinical trial of WSD0922-FU for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with thrid-generation EGFR-TKI .

Read the detailed description

WSD0922-FU is a potent reversible inhibitor of both the single EGFRm+ and dual EGFRm+/C797S+ receptor forms of EGFR with selectivity margin over wild-type EGFR. This study aims to explore the safety, tolerability, pharmacokinetic characteristics and efficacy of WSD0922-FU in patients with non-small cell lung cancer (NSCLC) with C797S mutation after first-line third-generation EGFR-TKI resistance.

03

Conditions studied

  • EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

Keywords

  • NSCLC
  • EGFR
  • C797S
  • BM
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years old (including the threshold value), gender is not limited;
  • Locally advanced or NSCLC confirmed by pathology;
  • Patients who have been genetically tested to carry EGFR sensitive mutations;
  • Blood samples must be provided for testing and must be taken during or after disease progression following the last EGFR TKI inhibitor treatment;
  • Must have a minimum of >= 3 months;
  • At least one measurable tumor lesion according to version 1.1; Previous radiotherapy-treated lesions cannot be used as target lesions unless imaging studies show clear progression of the lesions.
  • Physical Status ( PS) score was 0-1;
  • Have full organ function;
  • Eligible patients (male and female) who are fertile must agree to use a reliable method ;
  • Subjects are required to give to this study before the experiment and sign a written informed consent voluntarily.

Exclusion criteria

Exclusion Criteria:

  • Received chemotherapy, radiotherapy, biological therapy, targeted therapy, endocrine therapy, immunotherapy, or other anti-tumor drug treatments within 4 weeks before the first administration of the study drug.
  • Have previously received more than one EGFR-TKI inhibitor;
  • Received other unlisted clinical study drugs or treatments within 4 weeks before the first administration.
  • Received major organ surgery (excluding puncture ) or significant trauma within 4 weeks before the first administration, or require elective surgery during the trial period.
  • Used strong inhibitors or strong CYP3A4 inducers within 7 days before the first use of the study drug.
  • Known active or progression evidence.
  • Other primary malignant tumors within 2 years before the first administration of the study drug.
  • Adverse reactions from previous anti-tumor treatments have not recovered to v5.0 grade ≤1 (except for toxicities judged by the researcher to have no safety risks, such as hair loss, grade 2 peripheral neurotoxicity, and stable thyroid function after hormone replacement therapy).
  • Skin/pressure ulcers, chronic leg ulcers, known active gastric ulcers, or non-healing wounds.
  • History of severe allergies, or allergies to any active or inactive ingredients of the study drug;
  • Severe infections requiring intravenous antibiotic infusion or hospitalization at the time of screening; or uncontrollable active infections within 4 weeks before administration;
  • Known active or suspected diseases; or known active ocular diseases (such as active wet age-related macular degeneration, diabetic retinopathy with macular edema);
  • (HIV) (HIV1/2 antibody) positive, syphilis spirochete antibody positive .
  • Patients with interstitial lung disease.
  • History of severe cardiovascular diseases.
  • Unable to orally swallow medication, or there is a condition that significantly affects gastrointestinal absorption as judged by the researcher;
  • Clinical intervention is required for pleural effusion, ascites (excluding subjects who do not need drainage and have been stable for more than 2 weeks after drainage).
  • Known alcohol or drug dependence.
  • Mental disorders or poor compliance;
  • Pregnant or lactating women;
  • The investigator believes that the subject has other reasons that make them unsuitable for participating in this clinical study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Dose escalation (WSD0922-FU)

    Patients receive WSD0922-FU PO QD on C0D1 to C0D3, then BID on C1D1 to C1D21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and blood sample collection on study.

    Drug: WSD0922-FU

  • Experimental
    Dose expansion (WSD0922-FU)

    Patients receive WSD0922-FU PO BID on C1D1 to C1D21 using dosage selected from Dose escalation. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and blood sample collection on study.

    Drug: WSD0922-FU

Interventions

  • Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI Drug: WSD0922-FU Given PO

    Also known as: WSD0922

06

What researchers measure

Primary outcomes

  1. ORR by IRC

    proportion of patients with a best overall response of complete response or partial response

    Time frame: every 6 weeks, up to 1 year

  2. PartA: To evaluate the safety of WSD0922-FU in patients with NSCLC

    Safety (incidence and severity of adverse events \[AE\])

    Time frame: 8 months

  3. PartA: To evaluate the tolerability of WSD0922-FU in patients with NSCLC

    Incidence and quantity of dose-limiting toxicity (DLT)

    Time frame: 8 months

  4. PartA: To evaluate the Maximum Tolerated Dose (MTD) of WSD0922-FU in patients with NSCLC

    Incidence of Dose-Limiting Toxicities (DLTs)

    Time frame: 8 months

  5. PartA: Recommended Phase II Dose (RP2D) of WSD0922-FU in patients with NSCLC

    Recommended Phase II Dose (RP2D)

    Time frame: 8 months

Secondary outcomes

  1. PK exposure parameter: Maximum Plasma Concentration (Cmax)

    Maximum Plasma Concentration (Cmax)

    Time frame: 12 months

  2. PK exposure parameter: Time To Maximum Plasma Concentration (Tmax)

    Time To Maximum Plasma Concentration (Tmax)

    Time frame: 12 months

  3. PK exposure parameter: Area Under The Plasma Concentration-Time Curve From Time Zero To Time With Last Measurable Concentration (AUC0-t)

    Area Under The Plasma Concentration-Time Curve From Time Zero To Time With Last Measurable Concentration (AUC0-t)

    Time frame: 12 months

  4. PK exposure parameter: Area Under The Plasma Concentration-Time Curve From Time Zero To Infinity (AUC0-∞)

    Area Under The Plasma Concentration-Time Curve From Time Zero To Infinity (AUC0-∞)

    Time frame: 12 months

  5. PK exposure parameter: Terminal Elimination Half-Life (t½)

    Terminal Elimination Half-Life (t½)

    Time frame: 12 months

  6. PK exposure parameter: Apparent Terminal Elimination Rate Constant (λz)

    Apparent Terminal Elimination Rate Constant (λz)

    Time frame: 12 months

  7. PK exposure parameter: Apparent Clearance (CL)

    Apparent Clearance (CL)

    Time frame: 12 months

  8. PK exposure parameter: Apparent volume of distribution (Vd)

    Apparent volume of distribution (Vd)

    Time frame: 12 months

  9. PK exposure parameter: Mean Residence Time (MRT)

    Mean Residence Time (MRT)

    Time frame: 12 months

  10. Steady state pharmacokinetic parameter: Area Under the Steady-State Concentration-Time Curve(AUCss)

    Area Under the Steady-State Concentration-Time Curve(AUCss)

    Time frame: 12 months

  11. Steady state pharmacokinetic parameter: Area Under the Steady-State Concentration-Time Curve from 0 to Infinity(AUC0-∞,ss)

    Area Under the Steady-State Concentration-Time Curve from 0 to Infinity(AUC0-∞,ss)

    Time frame: 12 months

  12. Steady state pharmacokinetic parameter: Area Under the Steady-State Concentration-Time Curve from 0 to Time t (AUC0-t,ss)

    Area Under the Steady-State Concentration-Time Curve from 0 to Time t (AUC0-t,ss)

    Time frame: 12 months

  13. Steady state pharmacokinetic parameter: Average Steady-State Concentration(Cav)

    Average Steady-State Concentration(Cav)

    Time frame: 12 months

  14. Steady state pharmacokinetic parameter: Steady-State Clearance(CLss)

    Steady-State Clearance(CLss)

    Time frame: 12 months

  15. PK exposure parameter :Maximum Steady-State Concentration(Cmax,ss)

    Maximum Steady-State Concentration(Cmax,ss)

    Time frame: 12 months

  16. PK exposure parameter : Minimum Steady-State Concentration(Cmin,ss)

    Minimum Steady-State Concentration(Cmin,ss)

    Time frame: 12 months

  17. PK exposure parameter : Trough Concentration(Ctrough)

    Trough Concentration(Ctrough)

    Time frame: 12 months

  18. PK exposure parameter : Fluctuation Degree(DF)

    Fluctuation Degree(DF)

    Time frame: 12 months

  19. PK exposure parameter : Accumulation Ratio(Ra)

    Accumulation Ratio(Ra)

    Time frame: 12 months

  20. PK exposure parameter : Time to Maximum Concentration at Steady State(Tmax,ss)

    Time to Maximum Concentration at Steady State(Tmax,ss)

    Time frame: 12 months

  21. PK exposure parameter : Volume of Distribution Calculated from the Terminal Elimination Phase(Vz)

    Volume of Distribution Calculated from the Terminal Elimination Phase(Vz)

    Time frame: 12 months

  22. To evaluate the safety of WSD0922-FU in patients with advanced non-small cell lung cancer

    Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events (TRAEs)

    Time frame: 12 months

  23. ORR by investigators

    proportion of patients with a best overall response of complete response or partial response

    Time frame: every 6 week, up to 12 months

  24. Disease Control Rate (DCR)

    the percentage of patients who have a best overall response of CR or PR or SD

    Time frame: every 6 weeks, up to12 months

  25. Duration of Response (DoR)

    proportion of patients with the time from the date of first documented response until the date of documented progression or death in the absence of disease progression

    Time frame: every 6 weeks, up to 12 months

  26. PFS

    proportion of patients with the time from randomization until the date of objective disease progression or death

    Time frame: every 6 weeks, up to 12 months

  27. OS

    proportion of patients with the time from randomization until the date of objective disease progression or death

    Time frame: 24 months

07

Study locations

12 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jun 2027, 33 months after the start.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 33 months is below that.

Counting every sponsor, half of 435 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2024
First posted
Oct 8, 2024
StartActual
Sep 4, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 12, 2026
Enrollment
100 (estimated)→60 (actual)
Nov 12, 2026
Interventions
Arms removed: Dose extension (WSD0922-FU)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Active, not recruiting
    Enrollment 100 (estimated)→60 (actual)
    Interventions Arms removed: Dose extension (WSD0922-FU)
    + 4 other changes: verification date, design details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06631989
Lead sponsor
Wayshine Biopharm, Inc.
Responsible party
Sponsor
First posted
Oct 8, 2024
Start date
Sep 4, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Caicun Zhou, MD
principal investigator · Shanghai East Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EGFR/EGFRvIII Inhibitor WSD0922-FU

Start the discussion